Life Extension Final Clerance Sale

High Blood Pressure References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Lloyd-Jones et al. Heart Disease and Stroke Statistics—2010 Update. Circulation.2010; 121: e46-e215. 2009 Dec.
  2. Lloyd-jones et al. Hypertension in Adults Across the Age Spectrum. JAMA. 2005;294(4):466-472. doi: 10.1001/jama.294.4.466
  3. Roger VL. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-e209. Epub 2010 Dec 15.
  4. Kshirsagar AV et al. Blood pressure usually considered nromal is associated with an elevated risk of cardiovascular disease. Am J Med. 2006 Feb;119(2):133-41.
  5. Hyman DJ pavlik VN. Poor hypertension control: let’s stop blaming the patients. Cleve Clin J Med. 2002 Oct;69(10):793-9.
  6. Lewington, Sarah et al. “Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: a Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies..” The Lancet 2002; 360(9349) : 1903–1913.
  7. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. Epub 2003 Dec 1.
  8. Versari D et al. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009 Nov;32 Suppl 2:S314-21.
  9. Rocha M et al. Oxidative stress and endothelial dysfunction in cardiovascular disease: mitochondria-targeted therapeutics. Curr Med Chem. 2010;17(32):3827-41.
  10. Hausberg M, Lang D et al. Large artery wall properties: what is relevant for the management of hypertension? Dtsch Med Wochenschr. 2005 Nov 18;130(46):2657-61.
  11. Palmieri V, Storto G et al. Relations of left ventricular mass and systolic function to endothelial function and coronary flow reserve in healthy, new discovered hypertensive subjects. J Hum Hypertens. 2005 Dec;19(12):941-50.
  12. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995 Sep; 18(3):181-96.
  13. Xu JZ et al. Impaired endothelial function in hypertensive patients with target organ damage. J Hum Hypertens. 2009 Nov;23(11):751-7. Epub 2009 Mar 5.
  14. Schmieder, Roland E. “End Organ Damage in Hypertension..” Deutsches Ärzteblatt International 2010; 107(49) : 866–873..
  15. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther 2010;4:383-413.
  16. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010 Jan;375(9709):132-40.
  17. Schnohr P. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. European Heart Journal 2002 Apr.;23(8):620-626.
  18. Basile JN. Rationale for fixed-dose combination therapy to reach lower blood pressure goals. South Med J. 2008 Sep;101(9):918-24.
  19. Bakris GL Current perspectives on hypertension and metabolic syndrome. J Manag Care Pharm. 2007 Jun;13(5 Suppl):S3-5.
  20. Russell M, Fleg JL, Galloway WJ et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes- the stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J. 2006 Nov;152(5):867-75.
  21. Chiong, Jun R et al. “Secondary Hypertension: Current Diagnosis and Treatment..” International Journal of Cardiology 2008; 124(1): 6–21.
  22. Carretero, O A, and S Oparil. “Essential Hypertension. Part I: Definition and Etiology..” Circulation 2000; 101(3): 329–335.
  23. Viera, Anthony J. “Predisease: When Does It Make Sense?.” Epidemiologic Reviews 2011; epub ahead of print.
  24. Vasan, R S et al. “Assessment of Frequency of Progression to Hypertension in Non-Hypertensive Participants in the Framingham Heart Study: a Cohort Study..” The Lancet 2001; 358(9294): 1682–1686.
  25. Gavras I, Gavras H. 'Volume-expanded' hypertension: the effect of fluid overload and the role of the sympathetic nervous system in salt-dependent hypertension. J Hypertens. 2012 Jan 5. [Epub ahead of print]
  26. Shi Y et al. Dietary sodium intake among Canadian adults with and without hypertension. Chronic Dis Can. 2011 Mar;31(2):79-87.
  27. He FJ and MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. Prog Cardiovasc Dis. 2010 Mar-Apr;52(5):363-82.
  28. Demarin V and Morovic S. [Salt consumption and cerebrovascular diseases]. Acta Med Croatica. 2010 May;64(2):123-8.
  29. Marion R. Pathophysiology and Treatment of Obesity Hypertension. Current Pharmaceutical Design. Vol 10, Issue 29.
  30. Reisin E. Obestiy and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am. 2009 May;93(3):733-51.
  31. Azuma T. Prolonged effects of participation in disaster relief operations after the Mid-Niigata earthquake on increased cardiovascular risk among local governmental staff. J Hypertens. 2010 Apr;28(4):695-702.
  32. Pilz S. Role of vitamin D in arterial hypertension. Expert Rev Cardiovasc Ther. 2010 Nov;8(11):1599-608.
  33. Schurgers LJ , Spronk HM , Soute BA, Schiffers PM, DeMey JG, Vermeer C . Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2007 Apr 1;109(7):2823-31.
  34. Heran BS et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2008 Oct 8;(4):CD003822.
  35. Bangalore S et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011 Apr 26;342:d2234. doi: 10.1136/bmj.d2234.
  36. Benigni A et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest. 2009 Mar;119(3):524-30. doi: 10.1172/JCI36703.
  37. Cassis P et al. Angiotensin receptors as determinants of life span. Pflugers Arch. 2010 Jan;459(2):325-32. Epub 2009 Sep 11.
  38. Stegbauer J and Coffman TM. New insights into angiotensin receptor actions: from blood pressure to aging. Curr Opin Nephrol Hypertens. 2011 Jan;20(1):84-8.
  39. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe Spruelike Enteropathy Associated With Olmesartan. Mayo Clin Proc. 2012 Jun 22. [Epub ahead of print]
  40. Hermida RC et al. ime Dosing of Antihypertensive Medications Reduces Cardiovascular Risk in CKD. J Am Soc Nephrol. 2011 Oct 24. [Epub ahead of print]
  41. The Trials of Hypertension Prevention Collaborative Research Group. Effects of Weight Loss and Sodium Reduction Intervention on Blood Pressure and Hypertension Incidence in Overweight People with High-Normal Blood Pressure. Phase II. Archives of Internal Medicine 1997; 157(6): 657–667.
  42. He, J et al. “Long-Term Effects of Weight Loss and Dietary Sodium Reduction on Incidence of Hypertension..” Hypertension 2000: 35(2): 544–549.
  43. Cornelissen V, Fagard R. Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. J. Hypertens. 2005;
  44. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure : A meta-analysis of randomized controlled trials. Hypertension 2000 Mar.;35(3):838–843.
  45. Xin X, He J, Frontini M, Ogden L. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38:1112
  46. Sacks F, Svetkey L, Vollmer W, Appel L. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;
  47. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999 Feb 8;159(3):285-93
  48. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. New England Journal of Medicine 1997; 336:1117-1124
  49. Greger J. Nondigestible carbohydrates and mineral bioavailability. J Nutr 1999; Jul;129(7 Suppl):1434S-5S.
  50. Streppel MT, Arends LR, van t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005 Jan.;165(2):150–156.
  51. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J. Hypertens. 2005 Mar.;23(3):475–481.
  52. Myers VH, Champagne CM. Nutritional effects on blood pressure. Curr. Opin. Lipidol. 2007 Feb.;18(1):20–24.
  53. Altorf-van der Kuil W, Engberink MF, Brink EJ, van Baak MA, Bakker SJL, Navis G, van t Veer P, Geleijnse JM. Dietary protein and blood pressure: a systematic review. PLoS ONE 2010;5(8):e12102.
  54. Lane M, Black A and Ingram D. Calorie restriction in nonhuman primates: implications for age-related disease risk. Journal of Anti-Aging 1998;
  55. Walford RL, Mock D, Verdery R and MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57(6):B211-224
  56. Fontana L, Meyer TE, Klein S and Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA. 2004;101(17):6659-6663
  57. Fontana L, Klein S, Holloszy JO and Premachandra BN. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232-3235
  58. Meyer TE, Kovács SJ, Ehsani AA, Klein S, Holloszy JO and Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006;47(2):398-402
  59. Fontana L, Villareal DT, Weiss EP, Racette SB, Steger-May K, Klein S, Holloszy JO, and the Washington University School of Medicine CALERIE Group. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am J Physiol Endocrinol Metab 2007 Jul.;293(1):E197–202.
  60. Lefevre M, Redman LM, Heilbronn LK, Smith JV, Martin CK, Rood JC, Greenway FL, Williamson DA, Smith SR, Ravussin E, Pennington CALERIE Team. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis 2009 Mar.;203(1):206–213.
  61. Riordan MM, Weiss EP, Meyer TE, Ehsani AA, Racette SB, Villareal DT, Fontana L, Holloszy JO, Kovács SJ. The effects of caloric restriction- and exercise-induced weight loss on left ventricular diastolic function. Am J Physiol Heart Circ Physiol 2008 Mar.;294(3):H1174–82.
  62. Bloomer RJ, Kabir MM, Canale RE, Trepanowski JF, Marshall KE, Farney TM, Hammond KG. Effect of a 21 day Daniel Fast on metabolic and cardiovascular disease risk factors in men and women. Lipids Health Dis 2010;9:94.
  63. Natoli AK, Medley TL et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. Hypertension. 2005 Nov;46(5):1129-34.
  64. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005 Aug;46(2):249-54.
  65. Takahashi, K., Okada, M., et al. Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod. 2000;15(5): 1028-1036.
  66. Hayashi T, Ito I, Kano H, et al. Estriol (E3) Replacement Improves Endothelial Function and Bone Mineral Density in Very Elderly Women. J Gerontol A Biol Sci Med Sci. 2000;55(4):B183-B190.
  67. Kano, H., Hayashi, T., et al. Estriol retards and stabilizes atherosclerosis through an NO-mediated system. Life Sci. 2002;71(1): 31-42.
  68. Ichikawa A et al. Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma bradykinin levels and blood pressure in normotensive postmenopausal women. Geriatr Gerontol Int. 2008 Dec;8(4):259-64.
  69. Torkler S et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2010 Nov 19.
  70. Mizushima S, Cappuccio FP, Nichols R, Elliott P. Dietary magnesium intake and blood pressure: a qualitative overview of the observational studies. J Hum Hypertens 1998 Jul.;12(7):447–453.
  71. Houston MC, Harper KJ. Potassium, magnesium, and calcium: their role in both the cause and treatment of hypertension. J Clin Hypertens (Greenwich) 2008 Jul.;10(7 Suppl 2):3–11.
  72. Dickinson HO, Nicolson DJ, Campbell F, Beyer FR, Mason J. Potassium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev 2006;3:CD004641.
  73. Rosanoff A. Magnesium supplements may enhance the effect of antihypertensive medications in stage 1 hypertensive subjects. Magnes Res 2010 Mar.;23(1):27–40.
  74. Slutsky L et al. Enhancement of learning and memory by elevating brain magnesium. Neuron. 2010 Jan 28;65(2):165-77.
  75. Graham JD. Crataegus Oxyacantha in Hypertension. Br Med J 1939 Nov.;2(4114):951–953.
  76. Furey A, Tassell M. Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (Crataegus spp.). European Journal of Heart Failure 2008 Dec.;10(12):1153–1157.
  77. Pittler MH et al. Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005312.
  78. Walker AF, Marakis G, Simpson E, Hope JL, Robinson PA, Hassanein M, Simpson HCR. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2006 Jun.;56(527):437–443.
  79. Asgary S, Naderi GH, Sadeghi M, Kelishadi R, Amiri M. Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs Exp Clin Res 2004;30(5-6):221–225.
  80. Krishna G and Kapoor S. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention. Kidney International (1993) 43, 1097–1103; doi:10.1038/ki.1993.154
  81. Cappuccio FP, MacGregor GA. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J. Hypertens. 1991 May;9(5):465–473.
  82. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997 May;277(20):1624–1632.
  83. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003 Jul.;17(7):471–480.
  84. Food and Nutrition Board, Institute of Medicine (2005). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. Washington, DC, National Academy Press.
  85. 84A. U.S. Department of Agriculture (USDA). National Nutrient Database for Standard Reference, Release 20. 2007.

  86. Nicklas et al. The role of dairy in meeting the recommendations for shortfall nutrients in the American diet. J Am Coll Nutr 2009; 28 Suppl 1: 73S-81S
  87. Hamet P. The evaluation of the scientific evidence for a relationship between calcium and hypertension. J Nutr 1995 Feb.;125(2 Suppl):311S–400S.
  88. Resnick LM, Gupta rK, Bhargava KK, et al. Cellular ions in hypertension, diabetes and obesity: a nuclear magnetic resonance spectroscopic study. Hypertension. 1991;17:951–957.
  89. van Mierlo LAJ, Arends LR, Streppel MT, Zeegers MPA, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens 2006 May;20(8):571–580.
  90. Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors 2008;32(1-4):145–149.
  91. Digiesi V, Cantini F, Bisi G, GUARINO GC, ORADEI A, LITTARRU GP. Mechanism of action of coenzyme Q10 in essential hypertension. Current therapeutic research 1992;51(5):668–672.
  92. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong J-Y, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 2007 Apr.;21(4):297–306.
  93. Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev 2009;(4):CD007435.
  94. Chew GT et al. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care. 2008 Aug;31(8):1502-9. Epub 2008 May 16.
  95. Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, Dogra G, Watts GF. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens. 2009 Sep.;27(9):1863–1872.
  96. Hozawa A, Jacobs DR, Steffes MW, Gross MD, Steffen LM, Lee D-H. Circulating carotenoid concentrations and incident hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J. Hypertens. 2009 Feb.;27(2):237–242.
  97. Engelhard YN, Gazer B, Paran E. Natural antioxidants from tomato extract reduce blood pressure in patients with grade-1 hypertension: a double-blind, placebo-controlled pilot study. Am. Heart J. 2006 Jan.;151(1):100.
  98. Chen Z-Y, Peng C, Jiao R, Wong YM, Yang N, Huang Y. Anti-hypertensive nutraceuticals and functional foods. J Agric Food Chem 2009 Jun.;57(11):4485–4499.
  99. Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J. Hypertens. 2005 May;23(5):921.
  100. Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Antihypertensive Effect of Green Coffee Bean Extract on Mildly Hypertensive Subjects. Hypertens. Res. 2005;28(9):711–718.
  101. Yamaguchi T, Chikama A, Mori K. Hydroxyhydroquinone-free coffee: A double-blind, randomized controlled dose-response study of blood pressure. Nutrition 2008.
  102. Leclerc PC, Proulx CD, Arguin G, Bélanger S, Gobeil F, Escher E, Leduc R, Guillemette G. Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II. Am. J. Hypertens. 2008 Jan.;21(1):67–71.
  103. Bates CJ, Walmsley CM, Prentice A, Finch S. Does vitamin C reduce blood pressure? Results of a large study of people aged 65 or older. J. Hypertens. 1998 Jul.;16(7):925.
  104. Block G, Jensen CD, Norkus EP, Hudes M, Crawford PB. Vitamin C in plasma is inversely related to blood pressure and change in blood pressure during the previous year in young Black and White women. Nutr J 2008;7:35.
  105. Mahajan AS, Babbar R, Kansal N, Agarwal SK, Ray PC. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J Clin Biochem Nutr 2007 Mar.;40(2):141–147.
  106. Sato K, Dohi Y, Kojima M, Miyagawa K, Takase H, Katada E, Suzuki S. Effects of ascorbic acid on ambulatory blood pressure in elderly patients with refractory hypertension. Arzneimittelforschung 2006;56(7):535–540.
  107. Ward NC, Hodgson JM, Croft KD, Burke V, Beilin LJ, Puddey IB. The combination of vitamin C and grape-seed polyphenols increases blood pressure: a randomized, double-blind, placebo-controlled trial. J. Hypertens. 2005 Feb.;23(2):427–434.
  108. Duffy S, Gokce N, Holbrook M, Huang A, Frei B. Treatment of hypertension with ascorbic acid. The Lancet 1999; Dec 11;354(9195):2048-9.
  109. Fotherby MD, Williams JC, Forster LA, Craner P, Ferns GA. Effect of vitamin C on ambulatory blood pressure and plasma lipids in older persons. J. Hypertens. 2000 Apr.;18(4):411.
  110. Hajjar IM, George V, Sasse EA, Kochar MS. A Randomized, Double-Blind, Controlled Trial of Vitamin C in the Management of Hypertension and Lipids. Am J Ther 2002;9(4):289.
  111. Kim M, Sasaki S, Sasazuki S, Okubo S. Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension 2002; 40:797-803
  112. Ghosh SK, Ekpo EB, Shah IU, Girling AJ, Jenkins C, Sinclair AJ. A Double-Blind, Placebo-Controlled Parallel Trial of Vitamin C Treatment in Elderly Patients with Hypertension. Gerontology 1994;40(5):268–272.
  113. Magen E, Viskoper R, Mishal J, Priluk R. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr. Med. Assoc. J. 2004;
  114. Clouatre, D., Kandaswami, C and Connolly, KM. Grape Seed Extract. In Encyclopedia of Dietary Supplements, 2nd Edition. P. M. Coates, J. M. Betz, M. R. Blackman et al. New York, NY, Informa Healthcare: 2010; 916.
  115. Siva B, Edirisinghe I, Randolph J, Steinberg F. Effect of polyphenolics extracts of grape seeds (GSE) on blood pressure (BP) in patients with metabolic syndrome (MetS). FASEB J 2006;
  116. Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metab. Clin. Exp. 2009 Dec.;58(12):1743–1746.
  117. The Effect of Grape Seed Extract on Blood Pressure in People with Pre-Hypertension . Clinicaltrials.Gov. Web. 24 June 2011.
  118. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001 Sep.;158(1):195–198.
  119. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 2004 Jun.;23(3):423–433.
  120. Schlaich MP, Parnell MM, Ahlers BA, Finch S, Marshall T, Zhang W-Z, Kaye DM. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 2004 Dec.;110(24):3680–3686.
  121. Siani A, Pagano E, Iacone R, Iacoviello L, Scopacasa F, Strazzullo P. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am. J. Hypertens. 2000 May;13(5 Pt 1):547–551.
  122. Kelly BS, Alexander JW, Dreyer D, Greenberg NA, Erickson A, Whiting JF, Ogle CK, Babcock GF, First MR. Oral arginine improves blood pressure in renal transplant and hemodialysis patients. JPEN J Parenter Enteral Nutr 2001 Jun.;25(4):194–202.
  123. Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, Massarenti P, Settanni F, Casa Della L, Bergamini S, Iannone A. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008 May;31(5):940–944.
  124. Mahn K, Borrás C, Knock GA, Taylor P, Khan IY, Sugden D, Poston L, Ward JPT, Sharpe RM, Viña J, Aaronson PI, Mann GE. Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. FASEB J 2005 Oct.;19(12):1755–1757.
  125. Taku K, Lin N, Cai D, Hu J, Zhao X, Zhang Y, Wang P, Melby MK, Hooper L, Kurzer MS, Mizuno S, Ishimi Y, Watanabe S. Effects of soy isoflavone extract supplements on blood pressure in adult humans: systematic review and meta-analysis of randomized placebo-controlled trials. J. Hypertens. 2010 Oct.;28(10):1971–1982.
  126. Liu XX, Li SH, Chen JZ, Sun K, Wang XJ, Wang XG, Hui RT. Effect of soy isoflavones on blood pressure: A meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2011 Feb.;
  127. Jänicke, C., Grünwald, J., Brendler, T., 2003. Handbuch Phytotherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
  128. Somova LI, Shode FO, Ramnanan P, Nadar A. Antihypertensive, antiatherosclerotic and antioxidant activity of triterpenoids isolated from Olea europaea, subspecies africana leaves. J Ethnopharmacol 2003 Feb.;84(2-3):299–305.
  129. Somova LI, Shode FO, Mipando M. Cardiotonic and antidysrhythmic effects of oleanolic and ursolic acids, methyl maslinate and uvaol. Phytomedicine 2004 Feb.;11(2-3):121–129.
  130. Scheffler A, Rauwald HW, Kampa B, Mann U, Mohr FW, Dhein S. Olea europaea leaf extract exerts L-type Ca(2+) channel antagonistic effects. J Ethnopharmacol 2008 Nov.;120(2):233–240.
  131. Cherif S, Rahal N, Haouala M, Hizaoui B, Dargouth F, Gueddiche M, Kallel Z, Balansard G, Boukef K. [A clinical trial of a titrated Olea extract in the treatment of essential arterial hypertension]. J Pharm Belg 1996 Feb.;51(2):69–71.
  132. Scheller EF. [Treatment of hypertension with standardized olive leaf extract]. Med. Klin. (Munich) 1955 Feb.;50(8):327–329.
  133. Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, Schmidt A, Bradl B, Aydogan C. Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytother Res 2008 Sep.;22(9):1239–1242.
  134. Susalit E, Agus N, Effendi I, Tjandrawinata RR, Nofiarny D, Perrinjaquet-Moccetti T, Verbruggen M. Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine 2011 Feb.;18(4):251–258.
  135. Li Y. Vitamin D regulation of the renin–angiotensin system. Journal of cellular biochemistry 2003;
  136. Burgaz A, Orsini N, Larsson SC, Wolk A. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J. Hypertens. 2011 Apr.;29(4):636–645.
  137. Adams and Hewison. Update in vitamin D. J Clin Endocrinol Metab 2010;95 (2) :471-8
  138. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J. Hypertens. 2009 Oct.;27(10):1948–1954.
  139. Wu SH, Ho SC, Zhong L. Effects of vitamin D supplementation on blood pressure. South. Med. J. 2010 Aug.;103(8):729–737.
  140. Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007 Oct;58(5):513-22.
  141. Lafont A et al. Endothelial dysfunction and collagen accumulation: two independent factors for restenosis and constrictive remodeling after experimental angioplasty. Circulation. 1999 Sep 7;100(10):1109-15.
  142. Bellasi A, Lacey C, Taylor AJ, et al. Comparison of prognostic usefulness of coronary artery calcium in men versus women (results from a meta- and pooled analysis estimating all-cause mortality and coronary heart disease death or myocardial infarction). Am J Cardiol. 2007 Aug 1;100(3):409-14.
  143. Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol. 2001;90(Suppl):357-63.
  144. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA. 2003 Sep 30;100(20):11201-6.
  145. Beulens JW, Bots ML, Atsma F, et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2008 Jul 19.
  146. Schurgers LJ, Spronk HM, Skepper JN, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification.J Thromb Haemost. 2007 Dec;5(12):2503-11.
  147. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2008;8:13.
  148. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 2009 Jul.;32(7):365-372.
  149. Geleijnse JM, Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 2002 Aug.;20(8):1493–1499.
  150. Hartweg J, Farmer AJ, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 2007 Feb.;50(2):250–258.
  151. Matsumura Y, Kita S, Tanida Y, Taguchi Y, Morimoto S, Akimoto K, Tanaka T. Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats. Biol. Pharm. Bull. 1998 May;21(5):469–473.
  152. Kita S, Matsumura Y, Morimoto S, Akimoto K, Furuya M, Oka N, Tanaka T. Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Biol. Pharm. Bull. 1995 Sep.;18(9):1283–1285.
  153. Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, Matsumura Y. Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol. Pharm. Bull. 2002 Sep.;25(9):1247–1249.
  154. Sankar D, Rao MR, Sambandam G, Pugalendi KV. A pilot study of open label sesame oil in hypertensive diabetics. J Med Food 2006;9(3):408–412.
  155. Sankar D, Sambandam G, Ramakrishna Rao M, Pugalendi KV. Modulation of blood pressure, lipid profiles and redox status in hypertensive patients taking different edible oils. Clin. Chim. Acta 2005 May;355(1-2):97–104.
  156. Wu JHY, Hodgson JM, Clarke MW, Indrawan AP, Barden AE, Puddey IB, Croft KD. Inhibition of 20-hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies. Hypertension 2009 Nov.;54(5):1151–1158.
  157. Miyawaki T, Aono H, Toyoda-Ono Y, Maeda H, Kiso Y, Moriyama K. Antihypertensive effects of sesamin in humans. J. Nutr. Sci. Vitaminol. 2009 Feb.;55(1):87–91.
  158. Chitapanarux T, Tienboon P, Pojchamarnwiputh S, Leelarungrayub D. Open-labeled pilot study of cysteine-rich whey protein isolate supplementation for nonalcoholic steatohepatitis patients. J Gastroenterol Hepatol. 2009 Jun;24(6):1045-50.
  159. Laviolette L, Lands LC, Dauletbaev N, et al. Combined effect of dietary supplementation with pressurized whey and exercise training in chronic obstructive pulmonary disease: a randomized, controlled, double-blind pilot study. J Med Food. 2010 Jun;13(3):589-98.
  160. Marshall K. Therapeutic applications of whey protein. Altern Med Rev. 2004 Jun;9(2):136-56.
  161. Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity (Silver Spring). 2010 Jul;18(7):1354-9.
  162. Zhou A, Carrell RW, Murphy MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature. 2010 Nov 4;468(7320):108-11.
  163. Kawase M, Hashimoto H, Hosoda M, Morita H, Hosono A. Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J Dairy Sci. 2000 Feb;83(2):255-63.
  164. Pins JJ, Keenan JM. Effects of whey peptides on cardiovascular disease risk factors. J Clin Hypertens (Greenwich). 2006 Nov;8(11):775-82.
  165. Vermeirssen V, Van Camp J, Augustijns P, Verstraete W. Angiotensin-I converting enzyme (ACE) inhibitory peptides derived from pea and whey protein. Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2002;67(4):27-30.
  166. Manso MA, Lopez-Fandino R. Angiotensin I converting enzyme-inhibitory activity of bovine, ovine, and caprine kappa-casein macropeptides and their tryptic hydrolysates. J Food Prot. 2003 Sep;66(9):1686-92.
  167. Vermeirssen V, Van Camp J, Decroos K, Van Wijmelbeke L, Verstraete W. The impact of fermentation and in vitro digestion on the formation of angiotensin-I-converting enzyme inhibitory activity from pea and whey protein. J Dairy Sci. 2003 Feb;86(2):429-38.
  168. Abubakar A, Saito T, Kitazawa H, Kawai Y, Itoh T. Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion. J Dairy Sci. 1998 Dec;81(12):3131-8.
  169. Parrot S, Degraeve P, Curia C, Martial-Gros A. In vitro study on digestion of peptides in Emmental cheese: analytical evaluation and influence on angiotensin I converting enzyme inhibitory peptides. Nahrung. 2003 Apr;47(2):87-94.
  170. Vermeirssen V, Van Camp J, Devos L, Verstraete W. Release of angiotensin I converting enzyme (ACE) inhibitory activity during in vitro gastrointestinal digestion: from batch experiment to semicontinuous model. J Agric Food Chem. 2003 Sep 10;51(19):5680-7.
  171. Yamamoto N, Maeno M, Takano T. Purification and characterization of an antihypertensive peptide from a yogurt-like product fermented by Lactobacillus helveticus CPN4. J Dairy Sci. 1999 Jul;82(7):1388-93.
  172. Costa EL, Almeida AR, Netto FM, Gontijo JA. Effect of intraperitoneally administered hydrolyzed whey protein on blood pressure and renal sodium handling in awake spontaneously hypertensive rats. Braz J Med Biol Res. 2005 Dec;38(12):1817-24.
  173. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr. 2004 Apr;134(4):980S-8S.
  174. Maes W, Van Camp J, Vermeirssen V, et al. Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regul Pept. 2004 Apr 15;118(1-2):105-9.